Cybin is to meet with the UK’s Medical and Healthcare Products Regulatory Agency (MHRA) to discuss its lead psychedelic candidate CYB003 as a treatment for Major...
In a bid to help bring DMT and 5-MeO-DMT to patients, Biomind Labs has completed the development of its novel nasal gel delivery system.
Awakn has signed a Memorandum of Understanding (MOU) with the Devon Partnership NHS Trust and the University of Exeter to increase access to psychedelic-assisted therapy for...
Diamond Therapeutics has now dosed the first cohort of its Phase I low-dose psilocybin clinical trial.
Braxia Scientific Corp.
The first ketamine clinic in the UK has received approval from the Care Quality Commission (CQC) to begin treatments.
A philanthropic programme with a focus on the psychedelic sector has been launched to harness the power of innovative mental health approaches for social change.
Biotech company Cybin has filed an international patent application related to methods for the delivery of psychedelic medications.
A free, virtual event is to explore the use of psychedelics for alcohol use disorder and binge drinking.
Psychiatrist Dr Tiago Reis Marques discusses what new research findings on ketamine mean for treatment-resistant mental conditions such as major depressive disorder.
